Transaction DateRecipientSharesTypePriceValue
30th September 2020Charles B O'Keeffe7,000Open or private purchase$2.99$20,930.00
30th September 2020Patrick J Mcenany15,000Open or private purchase$2.97$44,550.00
5th December 2019Gary Ingenito150,000Open or private sale$4.82$723,150.00
4th December 2019Gary Ingenito150,000Exercise of derivative$2.53$379,500.00
27th November 2019Gary Ingenito100,000Exercise of derivative$1.13$113,000.00
27th November 2019Gary Ingenito100,000Open or private sale$4.66$466,000.00
21st November 2019Gary Ingenito100,000Open or private sale$4.50$449,800.00
20th November 2019Gary Ingenito100,000Exercise of derivative$0.79$79,000.00
11th October 2019Charles B O'Keeffe10,000Open or private purchase$4.70$46,950.00
3rd October 2019Patrick J Mcenany10,000Open or private purchase$4.89$48,900.00
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Catalyst Pharmaceuticals is a biopharmaceutical company. The company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL. It is developing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.

Ticker: CPRX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1369568
Employees: 76
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $115 M (0%)
Inventory, Net: $2 M (-6%)
Assets, Current: $131 M (17%)
Property, Plant and Equipment, Net: $168 Th (-20%)
Assets: $131 M (16%)
Accounts Payable, Current: $6 M (40%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $20 M (-16%)
Liabilities: $20 M (-18%)
Common Stock, Value, Issued: $103 Th (0%)
Common Stock, Shares, Issued: $103 M (0%)
Retained Earnings (Accumulated Deficit): $108 M (-15%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 Th (-87%)
Stockholders' Equity (Parent): $111 M (0%)
Liabilities and Equity: $131 M (16%)
Revenue: $30 M (-49%)
Cost of Revenue: $4 M (-50%)
Research and Development: $4 M (-49%)
Operating Income/Loss: $10 M (-50%)
Provision for income taxes: $613 Th (-49%)
EPS (basic): $0.09 (-55%)
EPS (diluted): $0.09 (-52%)